OPERATING INCOME SEK 10,0 million (6,2) JAN-JUN 2015

INTERIM REPORT JANUARY – JUNE 2015
For the April-June period

  ·
Net sales for the period were SEK 33.9 million (31.5).

  ·
Operating income (EBIT) for the period was SEK 4.2 million (2.0).

  ·
Operating margin for the period was 12 percent (6).

  ·
Earnings after tax for the period were SEK 0.4 million (0.4).

  ·
Earnings per share for the period, basic and diluted, were SEK 0.00 (0.00).

For the January-June period

  ·
Net sales for the period were SEK 67.6 million (62.1).

  ·
Operating income (EBIT) for the period was SEK 10.0 million (6.2).

  ·
Operating margin for the period was 15 percent (10).

  ·
Earnings after tax for the period were to SEK 5.9 million (1.6).

  ·
Earnings per share for the period, basic and diluted, were SEK 0.05 (0.01).

Significant events in the second quarter and after the balance sheet date.

  ·
No significant events occurred in the second quarter or after the balance sheet
date.

President and CEO Anders Karlsson’s comments on the first six months of 2015

     “Sales and profitability in the company continue to grow and over the first
six months of the year we have been seeing continued improvement in our
operating margin, now at 15 percent (10). Operating income (EBIT) amounted to
SEK 4.2 million (2.0) in the second quarter, and to SEK 10.0 million (6.2) for
the first half of the year. It is gratifying to see such strong performance in
the U.S, where sales were up 29 percent in the second quarter in local currency.
The extensive efforts we focused on in the American market during 2014 are now
bearing results, with sales increasing across the board for the company’s
product portfolio. We now look forward with confidence to the launch of our new
product QTYPE™, based on Real-Time PCR methodology, which will commence in the
second half of 2015.”

For more information please contact:

Anders Karlsson, CEO Allenex AB, and ph.: +4670-918 00 10, e-mail:
 (anders.karlsson@allenex.se)anders.karlsson@allenex.se
Yvonne Axelsson, CFO Allenex AB, and ph.: +468-508 939 72, e-mail:
yvonne.axelsson@allenex.se

Allenex AB discloses the information provided herein pursuant to the Securities
Markets Act and /or the Financial Instruments Trading Act. The information was
submitted for publication on Aug 27, 2015, at 13.00 CET. Allenex is a life
science-company that develops, manufacture, market and sell products for safer
transplants of organs and bone marrow on the global market. Allenex is listed on
NASDAQ OMX Stockholm Small Cap (ticker: ALNX). 55 persons are employed in the
Allenex group.